EUROSHOCK, NCT03813134: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock |
|
|
| Recruiting | N/A | 428 | Europe | Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO, Veno-Arterial Extra Corporeal Membrane Oxygenation. | University of Leicester, European Commission, University of Glasgow, KU Leuven, University of East Anglia, Deutsches Herzzentrum Muenchen, A.O. Ospedale Papa Giovanni XXIII, Chalice Medical Ltd, Ludwig-Maximilians - University of Munich, University of Tromso, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Paula Stradina Liniska Universitates, Accelopment AG, Universiteit Antwerpen, Cardiovascular European Research Centre (CERC) | Cardiogenic Shock | 03/23 | 02/24 | | |
| Recruiting | N/A | 768 | Europe, RoW | Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site. | Meril Life Sciences Pvt. Ltd. | Aortic Valve Stenosis | 03/24 | 12/33 | | |
